Predicted protein targets (top 14)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | NPY4R | P50391 | 12/20 | 0.41 |
| ▸ | NPY1R | P25929 | 7/20 | 0.41 |
| ▸ | NPY2R | P49146 | 5/20 | 0.39 |
| ▸ | NPY5R | Q15761 | 5/20 | 0.39 |
| ▸ | DPP7 | Q9UHL4 | 1/20 | 0.36 |
| ▸ | OTC | P00480 | 1/20 | 0.33 |
| ▸ | GNAI3 | P08754 | 1/20 | 0.33 |
| ▸ | GNAO1 | P09471 | 1/20 | 0.33 |
| ▸ | GNAI1 | P63096 | 1/20 | 0.33 |
| ▸ | ANPEP | P15144 | 2/20 | 0.33 |
| ▸ | RNPEP | Q9H4A4 | 2/20 | 0.33 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.33 |
| ▸ | DNPEP | Q9ULA0 | 1/20 | 0.33 |
| ▸ | DDAH1 | O94760 | 1/20 | 0.32 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL30531669 | 1.00 | NPY4R (0.41) | NPY4RNPY1RNPY2RNPY5RDPP7 | |
| SCHEMBL15653883 | 1.00 | NPY4R (0.41) | NPY4RNPY1RNPY2RNPY5RDPP7 | |
| SCHEMBL28712062 | 0.91 | NPY4R (0.39) | NPY4RNPY1RNPY2RNPY5RDPP7 | |
| SCHEMBL9237239 | 0.91 | NPY4R (0.39) | NPY4RNPY1RNPY2RNPY5RDPP7 | |
| SCHEMBL288133 | 0.91 | NPY4R (0.39) | NPY4RNPY1RNPY2RNPY5RDPP7 | |
| SCHEMBL1821005 | 0.90 | NPY4R (0.40) | NPY4RNPY1RNPY2RNPY5RDPP7 | |
| Hydrochloric Acid SCHEMBL8039440 | 0.89 | NPY4R (0.38) | NPY4RNPY1RNPY2RNPY5RDPP7 | |
| Hydrochloric Acid SCHEMBL8040222 | 0.89 | NPY4R (0.38) | NPY4RNPY1RNPY2RNPY5RDPP7 | |
| SCHEMBL3898461 | 0.89 | NPY4R (0.38) | NPY4RNPY1RNPY2RNPY5RDPP7 | |
| SCHEMBL1840068 | 0.88 | NPY4R (0.36) | NPY4RNPY1RNPY2RNPY5RDPP7 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 216 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3930666-B1 | ORAL CARE PRODUCT | COLGATE PALMOLIVE CO (US) | 2026-05-27 | — | — | EP | claimed |
| US-20250213449-A1 | Oral Care Product And Methods Of Use And Manufacture Thereof | COLGATE-PALMOLIVE COMPANY (US) | 2025-07-03 | — | — | US | claimed |
| US-20230078678-A1 | FORMULATIONS OF HUMAN ANTI-TSLP ANTIBODIES AND METHODS OF TREATING ATOPIC DERMATITIS | AMGEN INC. | 2023-03-16 | — | — | US | claimed |
| EP-4103235-A1 | FORMULATIONS OF HUMAN ANTI-TSLP ANTIBODIES AND METHODS OF TREATING INFLAMMATORY DISEASE | Amgen Inc. (US) | 2022-12-21 | — | — | EP | claimed |
| CN-115279404-A | Formulation of human anti-TSLP antibodies and methods of treating inflammatory diseases | 安进公司 | 2022-11-01 | — | — | CN | claimed |
| EP-3930666-A1 | ORAL CARE PRODUCT | Colgate-Palmolive Company (US) | 2022-01-05 | — | — | EP | claimed |
| CN-113543763-A | Oral care products | 高露洁-棕榄公司 | 2021-10-22 | — | — | CN | claimed |
| WO-2021163504-A1 | FORMULATIONS OF HUMAN ANTI-TSLP ANTIBODIES AND METHODS OF TREATING INFLAMMATORY DISEASE | AMGEN INC. (US) | 2021-08-19 | — | — | WO | claimed |
| US-20210127728-A1 | SYSTEMS AND METHODS FOR MONITORING OF FRACTIONAL GLUCONEOGENESIS AND TARGETING OF FRACTIONAL GLUCONEOGENESIS VIA NUTRITIONAL SUPPORT | RUN THEM SWEET LLC | 2021-05-06 | — | — | US | claimed |
| US-20210106039-A1 | SYSTEMS AND METHODS FOR MONITORING OF BLOOD LACTATE AND TARGETING OF BLOOD LACTATE VIA NUTRITIONAL SUPPORT | RUN THEM SWEET LLC | 2021-04-15 | — | — | US | claimed |
| US-9500657-B2 | Formulations containing labels for medical diagnostics | RUN THEM SWEET LLC (US) | 2016-11-22 | — | — | US | claimed |
| US-20160066609-A1 | BLOOD LACTATE RANGE TARGETS AND NUTRITIONAL FORMULATIONS AND PROTOCOLS TO SUPPORT PATIENTS | Run Them Sweet, LLC | 2016-03-10 | — | — | US | claimed |
| US-9232815-B2 | Blood lactate range targets and nutritional formulations and protocols to support patients | Run Them Sweet, LLC (US) | 2016-01-12 | — | — | US | claimed |
| EP-2912161-A2 | METHODS AND SYSTEMS TO ESTIMATE NUTRITIONAL NEEDS OF HUMAN AND OTHER PATIENTS AND TO SUPPORT SUCH NUTRITIONAL NEEDS | Run Them Sweet LLC (US) | 2015-09-02 | — | — | EP | claimed |
| US-20140356477-A1 | FORMULATIONS AND METHODS TO PROVIDE NUTRITION TO HUMAN AND OTHER PATIENTS | Run Them Sweet, LLC (US) | 2014-12-04 | — | — | US | claimed |
| US-20140121269-A1 | FORMULATIONS AND METHODS TO PROVIDE NUTRITION TO HUMAN AND OTHER PATIENTS | Run Them Sweet, LLC (US) | 2014-05-01 | — | — | US | claimed |
| US-20140120238-A1 | FORMULATIONS AND METHODS TO PROVIDE NUTRITION TO HUMAN AND OTHER PATIENTS | Run Them Sweet, LLC (US) | 2014-05-01 | — | — | US | claimed |
| US-20140121270-A1 | FORMULATIONS AND METHODS TO PROVIDE NUTRITION TO HUMAN AND OTHER PATIENTS | Run Them Sweet, LLC (US) | 2014-05-01 | — | — | US | claimed |
| US-20140121172-A1 | FORMULATIONS CONTAINING LABELS FOR MEDICAL DIAGNOSTICS | Run Them Sweet, LLC (US) | 2014-05-01 | — | — | US | claimed |
| WO-2014066628-A2 | METHODS AND SYSTEMS TO ESTIMATE NUTRITIONAL NEEDS OF HUMAN AND OTHER PATIENTS AND TO SUPPORT SUCH NUTRITIONAL NEEDS | Run Them Sweet, LLC (US) | 2014-05-01 | — | — | WO | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20230078678-A1 | FORMULATIONS OF HUMAN ANTI-TSLP ANTIBODIES AND METHODS OF TREATING ATOPIC DERMATITIS | TSLP, IL5, ORAI1 | NPY4R 2989/4885NPY1R 2246/4885NPY2R 3497/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.